Telix H1 2020 Results and Company Update Conference Call
Telix will hold an investor conference call to present the Company’s H1 2020 financial results together with an update on Telix’s...
Read moreLatest News
Category: ASX
Telix will hold an investor conference call to present the Company’s H1 2020 financial results together with an update on Telix’s...
Read moreTelix announces it has submitted a Drug Master File to the FDA for TLX101 (4-[131I]Iodol-phenylalanine...
Read moreTelix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th June 2020 and a Q2 2020 sales...
Read moreTelix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion...
Read moreTelix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal cancer imaging product...
Read moreTelix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings...
Read moreTelix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for...
Read moreTelix is pleased to provide the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of...
Read moreARTMS Products Inc. and Telix Pharmaceuticals Limited have entered into a development collaboration agreement...
Read more